Drug Trial Radar · NCT00411385
Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3
Last checked: Nov 19, 2026Latest source record: Aug 8, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
933
Actual
Start
Feb 2007
Primary completion
Oct 2008
Study completion Oct 2008
Sponsor
- Lead sponsor
- Human Genome Sciences Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Novartis
- First posted
- Dec 14, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 3, randomized, multi-center study to evaluate the efficacy and safety of albumin interferon alfa-2b (alb-IFN)in combination with ribavirin compared with peginterferon alfa-2a (PEGASYS or PEG-IFNa2a) in combination with ribavirin in subjects with chronic hepatitis C, genotype 2/3 who are IFNa treatment naive.
Conditions
- Chronic Hepatitis C
Interventions
albumin interferon alfa-2bDrug
900 and 1200 micrograms Albumin Interferon Alpha 2a given subcutaneously once every two weeks for 24 weeks
peginterferon alfa-2aDrug
180 micrograms Pegasys given subcutaneaously once a week for 24 weeks
RibavirinDrug
800mg/day for 24 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sustained virologic response (SVR)Time frame: Week 48
Locations
159 sites in 21 countries. Site status is shown where the registry gives one.
Mayo Clinic Hospital
Phoenix, Arizona
Scripps Clinic
La Jolla, California
California Pacific Medical Center
San Francisco, California
University of Colorado
Denver, Colorado
University of Florida-Gainesville
Gainesville, Florida
Shands Jacksonville Medical Center
Jacksonville, Florida
Mayo Clinic Transplant Center
Jacksonville, Florida
University of Miami
Miami, Florida
Atlanta Gastroenterology Associates
Atlanta, Georgia
GI of Atlanta
Atlanta, Georgia
University of Chicago Hospital
Chicago, Illinois
Johns Hopkins Center for Viral Hepatits
Baltimore, Maryland
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Minnesota Gastroenterology, P.A.
Plymouth, Minnesota
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire
University of New Mexico
Albuquerque, New Mexico
New York Hospital - Cornell
New York, New York
Faculty Practice Associates
New York, New York
NY Presbyterian Medical Center - Columbia Univ. Med Center
New York, New York
Bronx VA Medical Center
The Bronx, New York
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Regional Gastroenterology Associates of Lancaster, Ltd.
Lancaster, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania
Temple University Hospital
Philadelphia, Pennsylvania
Baylor University Medical Center
Dallas, Texas
Brooke Army Medical Center
Fort Sam Houston, Texas
Alamo Medrical Research
San Antonio, Texas
Metropolitan Research
Fairfax, Virginia
Unidad de Hepatología
Capital Federal, Buenos Aires, Argentina
Fundación Cidea
Capital Federal, Buenos Aires, Argentina
Hospital Italiano
Capital Federal, Buenos Aires, Argentina
Hospital Universitario Austral
Pilar, Buenos Aires, Argentina
Htal Pcial del Centenario
Rosario, Santa Fe Province, Argentina
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Concord Repatriation General Hospital
Concord, New South Wales, Australia
St George Hospital Clinical School of Medicine
Kogarah, New South Wales, Australia
John Hunter Hospital
New Lambton, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Gallipoli Research Foundation and Greenslopes Private Hospital
Greenslopes, Queensland, Australia
Royal Bribane & Women's Hospital
Herston, Queensland, Australia
Showing 40 of 159 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.